Fund Psychedelic Treatment Programs

What You Need To Know

• Psychedelics, such as ibogaine, psilocybin and ketamine, have been linked to the alleviation of various substance use disorders and may hold promise as potential treatments for Opioid Use Disorder. 

• Systematic reviews have concluded that prescribed psychostimulants for stimulant use disorder are well tolerated and not associated with serious adverse events (Source 1, 2)

• “The potential risks and benefits of prescribed psychostimulants must be weighed against the risks of harm from ongoing illegal stimulant use. Introducing prescribed psychostimulants for people already using illegal stimulants, alongside monitoring for adverse events, is a reasonable approach to reduce the harms associated with continued contact with an unregulated stimulant supply.”*

Research

• Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study

• Ketamine for the treatment of addiction: Evidence and potential mechanisms

• Incorporating prescription psychostimulants into the continuum of care for people with stimulant use disorder in Canada

• Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample

• Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. 

• Psychostimulant drugs for cocaine dependence. 

• Efficacy of psychostimulant drugs for amphetamine abuse or dependence